This brand name is authorized in Austria, Estonia, France, Croatia, Lithuania, Romania, United States
The drug ELREXFIO contains one active pharmaceutical ingredient (API):
|
1
Elranatamab
UNII L0HR9A577V - ELRANATAMAB
|
|
Elranatamab is a bi-specific T-cell engaging antibody that binds CD3-epsilon on T-cells and B-cell maturation antigen (BCMA) on plasma cells, plasmablasts, and multiple myeloma cells. Binding of elranatamab to BCMA on tumour cells and CD3 on T-cells is independent of native T-cell receptor (TCR) specificity or reliance on major histocompatibility (MHC) Class 1 molecules. Elranatamab activated T-cells, led to proinflammatory cytokine release, and resulted in multiple myeloma cell lysis. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| ELREXFIO Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ELREXFIO Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 3062933, 3062944 |
| Country: FR | Base de données publique des médicaments | Identifier(s): 65312065 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1098434, 1098435 |
| Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W70072001, W70072002 |
| Country: US | FDA, National Drug Code | Identifier(s): 0069-2522, 0069-4494, 63539-252 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
